Effects of curcumin and/or coenzyme Q10 supplementation on metabolic control in subjects with metabolic syndrome: a randomized clinical trial

Eighty-eight participants meeting the criteria for MetS were recruited and randomly assigned to four intervention groups. They consumed the supplements daily for 12 weeks, and assessments were made on various metabolic parameters.

This was a 2 × 2 factorial, randomized, double-blinded, placebo-controlled trial conducted over 12 weeks, involving 88 subjects with metabolic syndrome (MetS). Participants were assigned to four groups: curcumin plus placebo, coenzyme Q10 plus placebo, curcumin plus coenzyme Q10, or double placebo.

Curcumin was found to significantly reduce HDL-c, triglycerides, total cholesterol, and LDL-c compared to the other groups, indicating an improvement in dyslipidemia. However, there were no significant effects on body composition, blood pressure, or glycemic control. Coenzyme Q10 showed no therapeutic effects.

Did not assess dietary intake of curcumin and coenzyme Q10, nor were insulin levels measured, which are important for evaluating glycemic control. Additionally, subjects were enrolled sequentially, which may have introduced selection bias.